ABBADESSA, GIULIA
 Distribuzione geografica
Continente #
AS - Asia 88
EU - Europa 80
NA - Nord America 80
SA - Sud America 12
Continente sconosciuto - Info sul continente non disponibili 8
Totale 268
Nazione #
US - Stati Uniti d'America 74
SG - Singapore 34
RU - Federazione Russa 29
IT - Italia 25
VN - Vietnam 23
CN - Cina 16
BR - Brasile 9
CA - Canada 5
DE - Germania 5
HK - Hong Kong 5
NL - Olanda 5
FR - Francia 4
GB - Regno Unito 4
FI - Finlandia 3
AR - Argentina 2
IE - Irlanda 2
JP - Giappone 2
KR - Corea 2
BD - Bangladesh 1
IN - India 1
IQ - Iraq 1
JM - Giamaica 1
LT - Lituania 1
PE - Perù 1
PL - Polonia 1
SA - Arabia Saudita 1
TH - Thailandia 1
TW - Taiwan 1
UA - Ucraina 1
Totale 260
Città #
San Jose 21
Singapore 15
Moscow 11
Ashburn 9
Council Bluffs 9
Ho Chi Minh City 7
Beijing 6
Santa Clara 6
Hanoi 5
Naples 5
Boardman 4
Hong Kong 4
Arcore 3
Los Angeles 3
Basildon 2
Biên Hòa 2
Boston 2
Dublin 2
Frankfurt am Main 2
Hefei 2
Lauterbourg 2
Milan 2
Munich 2
Rome 2
Tokyo 2
Amsterdam 1
Araxá 1
Arequipa 1
Belo Horizonte 1
Brooklyn 1
Bắc Giang 1
Campinas 1
Cerrione 1
Changchun 1
Colônia Leopoldina Municipality 1
Cubatão 1
Erbil 1
Figino 1
Fredericton 1
Gimhae 1
Hat Yai 1
Helsinki 1
Houston 1
Hsinchu 1
Hải Dương 1
Jeddah 1
Juiz de Fora 1
Kyiv 1
Lappeenranta 1
Linhares 1
Lomas de Zamora 1
London 1
Machado 1
Mumbai 1
Muswell Hill 1
New York 1
Oklahoma City 1
Orem 1
Palermo 1
Paris 1
Perugia 1
Philadelphia 1
Phoenix 1
Port Hawkesbury 1
Quận Bình Thạnh 1
Redondo Beach 1
Salto 1
San Juan Bautista 1
Seoul 1
Simi Valley 1
St. Albert 1
Sterling Heights 1
Tampa 1
The Dalles 1
Turku 1
Warsaw 1
Windsor 1
Totale 182
Nome #
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors 136
Sexual dysfunction in people with multiple sclerosis: The role of disease severity, illness perception, and depression 109
Effect of dynamics and timing of SARS-CoV-2 vaccination on immune response in people with multiple sclerosis during cladribine treatment 12
Phase 1/2 study of pegenzileukin, a pegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers 6
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies 4
null 1
Totale 268
Categoria #
all - tutte 1.028
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.028


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20233 0 0 0 0 0 0 0 0 3 0 0 0
2023/20248 0 0 0 1 0 0 2 0 1 0 0 4
2024/202568 4 3 0 0 2 6 5 7 6 8 21 6
2025/2026158 11 10 18 13 29 6 21 8 19 16 3 4
2026/202731 16 15 0 0 0 0 0 0 0 0 0 0
Totale 268